Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Season 2, Episode 31, Jun 10, 06:46 PM
Share
Subscribe
Episode Description
In this podcast, experts Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO, and Fred Hirsch, MD, PhD, review the evolving treatment landscape for limited-stage small-cell lung cancer (LS-SCLC) and extensive-stage (ES) SCLC, including a discussion of the latest strategies for managing common and severe treatment-related adverse events.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from AstraZeneca.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Instructions on How to Receive Credit
In this podcast, experts Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO, and Fred Hirsch, MD, PhD, review the evolving treatment landscape for limited-stage small-cell lung cancer (LS-SCLC) and extensive-stage (ES) SCLC, including a discussion of the latest strategies for managing common and severe treatment-related adverse events.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from AstraZeneca.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Instructions on How to Receive Credit
- Listen to this podcast in its entirety.
- Go to gotoper.com/credit and enter code: 3451
- Answer the evaluation questions.
- Request credit using the drop-down menu.
You may immediately download your certificate.
Today's faculty are:
Fred Hirsch, MD, PhD, FASCO
Professor of Medicine and Pathology
Ning Zhao Chair Professor in Lung Cancer
Executive Director, Center for Thoracic Oncology
Associate Director of Biomarker Discovery, Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Advisory Board: AstraZeneca/Daiichi Sankyo, Agilent Technologies/Dako, Bristol Myers Squibb, Henlius/Fosun, Natera, Novartis Pharmaceuticals, Novocure, OncoHost
Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO
Director of Precision Oncology
Cincinnati Cancer Advisors
Cincinnati, OH
Disclosures: Consultant: Amgen, AstraZeneca, Pfizer; Speakers’ Bureau: Amgen, Astellas Pharma, AstraZeneca, GSK, Pfizer
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date: June 18, 2025
Expiration Date: June 18, 2026
Today's faculty are:
Fred Hirsch, MD, PhD, FASCO
Professor of Medicine and Pathology
Ning Zhao Chair Professor in Lung Cancer
Executive Director, Center for Thoracic Oncology
Associate Director of Biomarker Discovery, Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Advisory Board: AstraZeneca/Daiichi Sankyo, Agilent Technologies/Dako, Bristol Myers Squibb, Henlius/Fosun, Natera, Novartis Pharmaceuticals, Novocure, OncoHost
Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO
Director of Precision Oncology
Cincinnati Cancer Advisors
Cincinnati, OH
Disclosures: Consultant: Amgen, AstraZeneca, Pfizer; Speakers’ Bureau: Amgen, Astellas Pharma, AstraZeneca, GSK, Pfizer
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Release Date: June 18, 2025
Expiration Date: June 18, 2026